- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Sun Pharma, Alembic Pharma and 1 other recall products in US

Drug makers Sun Pharmaceutical Industries, Glenmark Pharmaceuticals, and Alembic Pharmaceuticals are recalling several products in the United States over manufacturing issues, the US Food and Drug Administration (USFDA) has said in its latest Enforcement Report.
Mumbai-based Glenmark is recalling two products from the US market. Its subsidiary, Glenmark Pharmaceuticals Inc, USA, is recalling Carvedilol tablets, prescribed for heart failure, hypertension, and heart attack, in multiple strengths.
The New Jersey-based firm is recalling 55,560 units of the affected lot due to "presence of a nitrosamine, N-Nitroso Carvedilol impurity above the current acceptable intake level," the USFDA stated.
The company is also recalling 17,496 bottles of Carvedilol tablets as "results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm," it added.
Glenmark initiated the Class II recall in August this year.
According to PTI, USFDA said the company is also recalling 22,656 bottles of Theophylline extended-release tablets (400 mg) for failed dissolution specifications.
Alembic Pharmaceuticals is recalling 9,492 bottles of Doxepin Hydrochloride capsules, used in the treatment of insomnia, the US health regulator stated.
The Class II recall is due to the "Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit," it said.
The company initiated the recall on July 25 this year.
New Jersey-based Sun Pharmaceutical Industries Inc is recalling 11,328 bottles of Spironolactone Tablets, used to treat high blood pressure, due to "Presence of foreign substance: identified as aluminum," the regulator said.
The company commenced the Class II recall on August 5.
As per the USFDA, a Class-II recall is initiated when the use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences, or when the likelihood of serious adverse health outcomes is minimal.The company initiated the recall on July 25 this year.
New Jersey-based Sun Pharmaceutical Industries Inc is recalling 11,328 bottles of Spironolactone Tablets, used to treat high blood pressure, due to "Presence of foreign substance: identified as aluminum," the regulator said.
The company commenced the Class II recall on August 5.
As per the USFDA, a Class-II recall is initiated when the use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences, or when the likelihood of serious adverse health outcomes is minimal.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751